Clinical trial
CCI-779 in Treating Patients With Metastatic Melanoma
NCT00022464 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00022464 |
|---|---|
| Title | CCI-779 in Treating Patients With Metastatic Melanoma |
| Official title | A Phase II Study Of CCI-779 (NSC 683864) In Metastatic Melanoma |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | temsirolimus |
| Start date | Jun 1, 2001 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 8, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: